The Evolving Landscape of Fecal Microbial Transplantation

Clin Rev Allergy Immunol. 2023 Oct;65(2):101-120. doi: 10.1007/s12016-023-08958-0. Epub 2023 Feb 9.

Abstract

The human gastrointestinal tract houses an enormous microbial ecosystem. Recent studies have shown that the gut microbiota plays significant physiological roles and maintains immune homeostasis in the human body. Dysbiosis, an imbalanced gut microbiome, can be associated with various disease states, as observed in infectious diseases, inflammatory diseases, autoimmune diseases, and cancer. Modulation of the gut microbiome has become a therapeutic target in treating these disorders. Fecal microbiota transplantation (FMT) from a healthy donor restores the normal gut microbiota homeostasis in the diseased host. Ample evidence has demonstrated the efficacy of FMT in recurrent Clostridioides difficile infection (rCDI). The application of FMT in other human diseases is gaining attention. This review aims to increase our understanding of the mechanisms of FMT and its efficacies in human diseases. We discuss the application, route of administration, limitations, safety, efficacies, and suggested mechanisms of FMT in rCDI, autoimmune diseases, and cancer. Finally, we address the future perspectives of FMT in human medicine.

Keywords: Autoimmune diseases; Cancer; Clostridium infections; Dysbiosis; Fecal microbiota transplantation (FMT); Gut microbiota.

Publication types

  • Review

MeSH terms

  • Clostridioides difficile* / physiology
  • Clostridium Infections* / therapy
  • Fecal Microbiota Transplantation
  • Feces
  • Humans
  • Microbiota*
  • Neoplasms*
  • Treatment Outcome